<DOC>
	<DOCNO>NCT00268723</DOCNO>
	<brief_summary>To determine administration levalbuterol tartrate HFA MDI subject EIB effective prevention EIB safe well-tolerated .</brief_summary>
	<brief_title>Efficacy Study Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo Subjects 18 Years Older With EIB</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multicenter , two-way crossover study levalbuterol tartrate HFA MDI subject 18 year age old EIB . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Bronchial Spasm</mesh_term>
	<mesh_term>Asthma , Exercise-Induced</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Inclusion Criteria Subjects males females 18 year age old time consent . Female subject consider childbearing potential either surgically sterile great oneyear postmenopausal , define complete cessation menstruation least one year . Female subject childbearing potential negative urine pregnancy test screening . Female subject childbearing potential agree use acceptable method birth control throughout study . Subjects good health suffer chronic condition might affect respiratory cardiac function ( include cardiac arrhythmia ) . Subjects document diagnosis exerciseinduced bronchospasm minimum 6 month prior study start . Subjects stable baseline asthma use beta2adrenergic agonist , and/or antiasthma antiinflammatory medication , and/or overthecounter asthma medication least 6 month prior study start . Exclusion Criteria Subjects currently diagnose lifethreatening asthma define history : asthma episodes require intubation , associate hypercapnia , respiratory arrest , hypoxic seizure within 12 month prior study start . Subjects history hospitalization asthma within 4 week prior study start , schedule inpatient hospitalization , include elective surgery , course trial . Subjects document history bronchopulmonary aspergillosis form allergic alveolitis . Subjects suffer clinically significant upper low respiratory tract infection 3 week prior study start . Subjects clinically significant unstable medical abnormality , chronic disease ( asthma ) , history clinically significant abnormality cardiovascular , gastrointestinal , respiratory , hepatic , renal , endocrine , central nervous system currently well control medication may interfere successful completion protocol . Subjects history cancer ( exception : basalcell carcinoma remission minimum 5 year ) . Subjects know sensitivity levalbuterol , racemic albuterol , excipients contain formulation . Subjects use prescription drug levalbuterol tartrate administration contraindicate . Subjects history substance abuse drug abuse within 12 month precede study start . Subjects participate investigational drug study within 30 day prior study start , currently participate another clinical trial . Subjects great 10packyear history cigarette smoking use tobacco product within 6 month study start . Subject staff member relative staff member . Subjects unstable asthma , change asthma therapy , visit emergency department hospital worsen asthma within 4 week study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>